![Natalie Sacks](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Natalie Sacks
Director/Board Member at
CARIBOU BIOSCIENCES, INC.
Net worth: - $ as of 2026-08-30
Profile
Natalie R.
Sacks is an Independent Director at Caribou Biosciences, Inc. since 2018.
Dr. Sacks is a Director at STipe Therapeutics ApS since 2020.
Dr. Sacks is a Partner at Novo Holdings Equity US, Inc. Former roles include Director at Zymeworks, Inc. from 2017 to 2023, Independent Director at Zymeworks BC, Inc., Vice President-Clinical Development at Cell Genesys, Inc. from 2002 to 2009, Vice President-Clinical Development at Onyx Pharmaceuticals, Inc. from 2011 to 2014, Vice President-Clinical Research at Exelixis, Inc. from 2009 to 2011, Chief Medical Officer at Aduro BioTech, Inc. from 2016 to 2018, Assistant Clinical Professor at The University of California, San Francisco from 2003 to 2016, and Chief Medical Officer at Harpoon Therapeutics, Inc. from 2018 to 2022.
Education includes undergraduate studies at Bryn Mawr College, graduate studies at Harvard T.H.
Chan School of Public Health, and a doctorate from Perelman School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-19 | 0 ( -.--% ) | - $ | 2026-08-30 |
Natalie Sacks active positions
| Companies | Position | Start |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 2018-04-30 |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops immune-oncology therapies | Director/Board Member | 2020-03-31 |
Novo Holdings Equity Us, Inc.
 Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies | Corporate Officer/Principal | - |
Former positions of Natalie Sacks
| Companies | Position | End |
|---|---|---|
| ZYMEWORKS INC. | Director/Board Member | 2023-06-29 |
| HARPOON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-05-31 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-08-31 |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 2015-12-31 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Chief Tech/Sci/R&D Officer | 2013-12-31 |
Training of Natalie Sacks
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
69
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Health Technology |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company, which focuses on the development of technology platforms for cancer | Health Technology |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
Bryn Mawr College
 Bryn Mawr College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Perelman School of Medicine
 Perelman School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops immune-oncology therapies | Health Technology |
Novo Holdings Equity Us, Inc.
Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies | Finance |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
- Stock Market
- Insiders
- Natalie Sacks
